50 results
8-K
EX-3.1
GOSS
Gossamer Bio Inc
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could … be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the Corporation will be entitled
424B3
GOSS
Gossamer Bio Inc
28 Aug 23
Prospectus supplement
4:29pm
or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation
S-3
GOSS
Gossamer Bio Inc
18 Aug 23
Shelf registration
8:41am
) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus, and (vi
S-3ASR
4ezbmppy3
17 Aug 23
Automatic shelf registration
4:01pm
8-K
EX-10.1
v60n73z1a5ddlkj2
20 Jul 23
Gossamer Bio Announces $212 Million Private Placement Financing
4:01pm
S-3ASR
jtf4v1wvo51
9 Aug 22
Automatic shelf registration
12:00am
S-3ASR
EX-4.4
212ziah1 624
3 Mar 22
Automatic shelf registration
4:05pm
8-K
EX-1.1
sxlju0ej6a7b8ry42s
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-4.1
vv3h6kx9ykd4hj 4uw7t
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-4.2
n2ne09y5 mwgeq
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.2
kym2xr
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm